This is the material for the clinical literature reading meeting held in our department.
Update information: November 20, 2024 No. 130 to No. 135 have been posted.
| update date | theme | |
| November 20, 2024 | No.135｜2024.11.14｜Lancet Rheumatol｜Pre RA TREAT EARLIER | |
|---|---|---|
| No.134｜2024.10.29｜A&R｜SLE_UPA+Elusubrutinib | ||
| No.133｜2024.10.22｜JAMA network open｜Efficacy of MMF in SLE without major organ involvement | ||
| No.132│2024.10.15│ARD│ Still disease EULAR PReS reccomendations | ||
| No.131│2024.10.08│ARD│BLISS-Believe | ||
| No.130｜2024.09.24｜Lancet｜SS iscalimab RCT phase2b (TWINSS) | ||
| November 14, 2024 | No.129｜2024.09.17｜ARD｜Apremilast-min for Oligoarticular PsA | |
| No.128｜2024.09.10｜Nature｜AMP-SLE TpH CXCL13 | ||
| No.127｜2024.09.03｜NEJM｜CAR-T SLE Summary | ||
| No.125｜2024.07.23｜ARD｜AAV post-RTX B cell analysis | ||
| July 24, 2024 | No.124｜2024.07.16｜NatMed｜RA BiTE Pilot Study | |
| No.123│2024.07.09│ARD│VEXAS Treatment outcomes Retrospective cohort | ||
| No.122│2024.07.02│ARD│MAINRITSAN Examination | ||
| No.121│2024.06.25│ARD│ARS cluster analysis | ||
| November 18, 2024 | No.120│2024.06.11│ARD│EULAR recommendation of PsA, 2023 | |
| No.119｜2024.06.04｜Rheumatology｜Anti-RibP antibodies and SLE | ||
| No.118｜2024.05.27｜ARD｜Anifrolumab Type I IFN signature | ||
| June 4, 2024 | No.117│2024.05.21│ACR Open Rheumatol│bDMARD tapering and predictors of RA flare-ups | |
| No.116｜2024.05.14｜Science Immunol｜ThA | ||
| No.115│2024.05.07│A&R│RA-related LPD Japanese multicenter cohort | ||
| No.114│2024.04.30│Lancet Rheumatol│preRA, ABT, RCT (APIPPRA study) | ||
| No.113│2024.04.23│Lancet Rheumatol│csDMARDs halving/gradual tapering/discontinuation (ARCTIC REWIND) | ||
| May 7, 2024 | No.112│2024.04.09│NEJM│Sarilumab for recurrent PMR (SAPHYR trial) | |
| No.111｜2024.04.02｜ARD｜Reduction of GC and immunosuppressants in maintenance IgG4-RD | ||
| No.110｜2024.03.26｜NEJM｜EGPA Benralizumab vs Mepolizumab (MANDARA) | ||
| No.109｜2024.03.19｜Kidney Int｜KDIGO LN guideline 2024 | ||
| March 19, 2020 | No.108｜2024.03.12｜Lancet Rheumatol｜Remission SLE MMF withdrawal non-inferiority study | |
| No.107│2024.03.05│ARD│AAV RTX mainenance Long term | ||
| No.106│2024.02.27│ARD│Telitacicept phase 2b in SLE | ||
| No.105｜2024.02.20｜ARD｜Avacopan+RTX ADVOCATE subgroup analysis | ||
| March 18, 2020 | No.104｜2024.02.13｜Nat Med｜Anti-TRBV9 AS | |
| No.103│2024.01.30│A&R│SS-A antibody titer and fetal AVB | ||
| No.102｜2024.01.23｜A&R｜Long-term results of VOC against LN (AURORA 2) | ||
| No.101｜2024.01.16｜Nature｜RA-SF scRNA-seq AMP phase II | ||
| No.100｜2024.01.09｜ARD｜JAKi review | ||
| November 24, 2020 | No.99｜2023.11.21｜ARD｜Long-term remission RA TNFi tapering non-inferiority study | |
| No.98｜2023.11.14｜A&R｜Relational analysis of HCQ adherence and SLE | ||
| November 9, 2020 | No.97｜2023.11.07｜ARD｜SLE 2023 reccomendation | |
| No.96｜2023.10.31｜Lancet Rheumatol｜FcgR2B+CD19 Obexelimab IgG4RD | ||
| October 27, 2020 | No.95｜2023.10.24｜A&R｜CAR-T SSc mouse model | |
| No.94│2023.10.17│ARD│APS 2023 classification criteria | ||
| No.93｜2023.10.03｜ARD｜Safety of MTX for men who wish to have children | ||
| September 29, 2020 | No.92｜2022.09.26｜ARD｜Anti-GM-CSF otilimab vs TOFA SAR contRAst | |
| No.91│2023.09.19│Lancet│JIA Baricitinib | ||
| No.90｜2023.09.12｜Forehead osteonecrosis position paper 2023 | ||
| September 12, 2020 | No.89｜2023.08.01｜ARD｜ICI-myositis transcriptome | |
| No.88｜2023.07.25｜Lancet Rheumatol｜GCA-SEC (TitAIN) | ||
| No.87│2023.07.11│Lancet Rheumatol│BILAG-BR, infection risk│ | ||
| No.86 | 2023.07.04 | Lancet Rheum | ICI for cancer-bearing patients with RA | ||
| No.85｜2022.06.27｜NEJM｜PD-1 agonist Ab for RA | ||
| June 27, 5th year of Reiwa | No.84｜2023.06.20｜Mod Rheumatol｜HCQ for RA | |
| No.83｜2023.06.13｜Lancet Rheumatol｜RTX for PMR | ||
| June 7, 2020 | No.82｜2023.06.06｜A&R｜Deucravacitinib for SLE P2 | |
| No.81｜2023.05.23｜ARD｜TULIP-LLDAS Analysis | ||
| June 6, 2023 | No.80│2023.05.09│ARD│2022 AAV Recommendation | |
| No.79｜2023.05.02｜ARD｜RITAZAREM | ||
| No.78｜2023.04.18｜A&R｜MDA5 3-group clustering | ||
| No.77｜2023.04.11｜Lancet｜BARI for SLE P3 | ||
| No.76│2023.03.28│ARD│ax-SpA bimekizumab phaseⅢ RCT | ||
| April 10, 2020 | No.75│2023.03.07│A&R│MTX withdrawal after influenza vaccine | |
| No.74｜2023.02.28｜ARD｜Treatment selection after JAKi falure | ||
| No.73｜2023.02.21｜ARD｜BEL and Pregnancy | ||
| No.72｜2023.02.14｜ARD｜anti-IFNa autoAb SLE Covid severe | ||
| No.71│2023.02.07│ARD│LUPIL-2, low dose IL-2 therapy, SLE | ||
| No.70│2023.01.31│Rheumatology│SSc-ILD framework | ||
| March 6, 2023 | No.69│2023.01.24│ARD│GCA US score(OGUS)│ | |
| No.68｜2023.01.17｜A&R｜TULIP LTE test | ||
| No.67│2023.01.10│ARD│RA Management Recommendation | ||
| No.66｜2022.12.13｜Lancet Rheumatol｜SLE LLDAS mortality | ||
| No.65｜2022.12.06｜ARD｜Summary of LVV classification criteria | ||
| November 30, 2020 | No.64│2022.11.22│ARD│axial SpA recommendation | |
| No.63│2022.11.15│ARD│Recommendations for Screening and Prevention of Opportunistic Infections in Rheumatic Diseases | ||
| No.62│2022.11.08│Mod Rheumatol│MTXsc RA | ||
| No.61｜2022.11.01｜NEJM｜IVIg for DM (ProDERM) | ||
| November 4, 2020 | No.60｜2022.10.25｜Lancet Rheumatol｜PGA | |
| No.59│2022.10.18│A&R│Ozoralizumab RCT | ||
| No.58│2022.10.11│JAMA│TCZ for GC-dependent PMR | ||
| October 5, 2020 | No.57│2022.10.04│Nat Med│Anti-CD19 CAR-T SLE | |
| No.56｜2022.09.27｜ARD｜SLE Bari cytokine | ||
| No.55│2022.09.13│ARD│GLORIA trial (65+RA, low dose PSL add on) | ||
| September 12, 2020 | No.54│2022.09.06│NEJM│CLE-Litifilimab | |
| August 4, 2020 | No.53│2022.07.26│ARD│LN Dose reduction in remission RCT | |
| No.52｜2022.07.19｜ARD｜Safety and efficacy of baricitinib for recurrent GCA | ||
| July 25, 2020 | No.51｜2022.07.12｜ARD｜TULIP-1&2 post hoc analysis | |
| No.50｜2022.07.05｜A&R｜TOFA safety | ||
| No.49｜2022.06.28｜ARD｜mavrilimumab-GCA | ||
| No.48｜2022.06.21｜ARD｜SSc-ILD module analysis and response to MMF treatment | ||
| June 24, 2020 | No.47｜2022.06.14｜JAMAnetwork｜LN Tac vs IVCY | |
| No.46｜2022.06.07｜ARD｜TCZ for PMR | ||
| No.45｜2022.05.31｜ARD｜EULAR recommendation CV risk | ||
| No.44｜2022.05.24｜A&R｜CANDLE Points to consider | ||
| No.43｜2022.05.17｜BMJ｜AAV PE systematic review | ||
| No.42｜2022.05.10｜ARD｜anifrolumab (TULIP-LN) for LN | ||
| No.41｜2022.04.19｜NEJM｜Iberdomide SLE | ||
| No.40｜2022.04.12｜ARD｜Bari safety | ||
| March 8, 2020 | No.39｜2022.03.02｜A&R｜GPA classification criteria | |
| No.38｜2022.02.16｜ARD｜MPA classification criteria | ||
| No.37｜2022.02.09｜ARD｜EGPA classification criteria | ||
| No.36｜2022.02.02｜Lancet｜SS ianalumab | ||
| No.35│2022.01.26│JAMA│NOR-DRUM B trial | ||
| January 26, 2020 | No.34｜2022.01.19｜Rheumatology｜Safety of Xingrix against IMID |
|
| No.33｜2022.01.12｜ARD｜NOBILITY phase2 Obinutuzumab LN | ||
| No.32｜2022.01.05｜Lupus Sci Med｜DORIS Remission | ||
| No.31｜2021.12.08｜A&R｜ACR AAV Guide | ||
| January 14, 2020 | No.30｜2021.11.24｜Rheumatology｜PET-CT evaluation of GCA during use of TCZ | |
| January 5, 2020 | No.29｜2021.10.06｜NPSLE summary | |
| No.28｜2021.09.22｜JCI｜pDC treatment (SLE) | ||
| No.27｜ 2021.09.15｜A&R SLE-PAH prediction model | ||
| November 10, 2021 | No.26｜2021.09.08｜A&R｜RA Guidelines | |
| No.25｜2021.09.01｜ARD｜GC canceled (BeSt, IMPROVED) | ||
| No.24｜2021.08.25｜ARD｜VEXAS-UBA1 and RP | ||
| August 11, 2021 | No.23｜2021.07.21｜A&R｜LVV Guidelines | |
| No.22｜2021.07.14｜ARD｜Treatment policy for pregnant RA patients | ||
| No.21｜2021.07.07｜Lancet｜LN AURORA1 | ||
| No.20｜2021.06.30｜ARD｜JAK inhibitor selectivity | ||
| No.19｜2021.06.23｜ARD｜ACR-CRISS | ||
| No.18｜2021.06.23｜JAMA｜AAV LoVAS | ||
| No.17｜2021.06.02｜ARD｜Immunosuppressants and mRNA vaccines | ||
| No.16｜2021.05.27｜ARD｜aPL in Covid19 | ||
| No.15｜2021.04.28｜A&R｜Fraktalkine phase 2 | ||
| No.14｜2021.04.14｜ARD｜RA-SF multi-omics | ||
| May 11, 2021 | No.13｜2021.03.31｜A&R｜HCQ thrombosis | |
| No.12｜2021.03.24｜Lancet Respir Med｜Nintedanib for SSc on MMF | ||
| No.11｜2021.03.17｜NEJM｜AAV Avacopan | ||
| No.10｜2021.03.10｜ARD｜SS ABA phase III | ||
| No.9｜2021.03.03｜A&R｜ustekinumab SLE | ||
| No.8｜2021.02.24｜Rheumatology｜gout- MSUS | ||
| No.7｜2021.02.17｜A&R｜ETN withdrawal | ||
| No.6｜2021.02.10｜ARD｜EUSTAR_SSc-ILD analysis | ||
| No.5｜2021.02.03｜ARD｜D2T-RA | ||
| No.4｜2021.01.27｜NEJM｜Upadacitinib vs ABT | ||
| No.3｜2021.01.20｜A&R｜TA-AAV | ||
| No.2｜2021.01.13｜ARD｜SLE-2019 Validation | ||
| No.1｜2021.01.06｜A&R｜MTX-IP |
